# PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

> **NCT04360941** · PHASE1 · RECRUITING · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 45 (estimated)

## Conditions studied

- Triple Negative Breast Cancer
- Locally Advanced Breast Cancer
- Recurrent Breast Cancer
- Metastatic Breast Cancer
- ER+ Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT04360941
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-11
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04360941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04360941, "PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04360941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*